CAS: 51-49-0; D-Thyroxine

该化合物是甲状腺腺生成的一种激素,在调节新陈代谢,生长和身体发育方面起着关键作用,是天然荷尔蒙的一种合成形式,通常用于治疗甲状腺运动.D-Thyroxine的化学配方是C15H11I4N0,其分子重量约为776.87克/摩尔.D-Thyroxine的特征是其晶体结构,其典型特征是白色到白色外表.它溶于水和酒精,但有机溶剂的溶解性有限.该物质在正常条件下稳定,但在接触光,热或湿气时可降解.其作用机制涉及甲状腺激素受体,影响基因表达和代谢过程.由于它具有重大的生理影响,D-Thyroxine必须谨慎地加以管理,并且在临床环境中对其剂量进行仔细监测,以避免与甲状腺激素不平衡的潜在副影响.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号300-30-1 甲状腺素 | CAS号5563-89-3 3,5-二碘-d-原氨酸 | CAS号534-51-0 3,5-二碘甲腺氨酸 | CAS号120408-14-2 N-formyl-3,5-di... | CAS号556-02-5 D-酪氨酸 | CAS号502481-41-6 N-acetyl-3,5-di... | CAS号16711-71-0 D-3,5-二碘酪氨酸

合成工艺路线路线简述

    📜3,5-二碘甲腺氨酸置于氨,水,氢溴酸,碘,(+)-1-Phenylethylamine体系中,化学反应生成 D-甲状腺素
    参考文献:Harington,Biochemical Journal,1928,Vol. 22,P. 1433
    标题:Harington,Biochemical Journal,1928,Vol. 22,P. 1433

    海关参考信息

    专利信息


    专利号:US-2021130409-A1
    优先权日:2017-09-01
    标 题 :Method for the Solid-Phase Synthesis of Cyclic Pentapeptides
    发明人:ZHENGGUO JIANG; LUCIANO FORNI; ROBERTSON ALAN
    权利人:Alsonex Pty Ltd
    摘要:A method for the synthesis of a cyclic ornithine-proline-D-cyclohexylalanine-tryptophan-arginine pentapeptide of Formula A; n n n n n n n n n n n n wherein R 1 and R 2 are, independently, —H, or —C(O)R 3 where R 3 is —CH 2 Ph, —CH 2 CH 2 Ph, —CHâ•?CHPh, —C(NHAC)CH 2 Ph;n nthe method comprising the steps of;n nforming a linear proline-D-cyclohexylalanine-tryptophan-arginine-ornithine pentapeptide of Formula B, attached to a polymeric resin;n n n n n n n n n n n n n n n n n wherein R 1 is as for Formula A, RES indicates the polymeric resin, and P 1 and P 2 are protecting groups;n ncyclising the linear pentapeptide of Formula B to form a cyclic pentapeptide of Formula C, attached to the polymeric resin;n n n n n n n n n n n n n n n cleaving the cyclic peptide of Formula C from the resin providing a cleaved cyclic pentapeptide having a free amine group of an ornithine residue;n noptionally substituting the free amine group of the ornithine residue of the cleaved cyclic peptide;n nremoving the protecting groups P 1 and P 2 , to providethe cyclic peptide of Formula A.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-4242256-A
    优先权日:1977-03-15
    标 题 :Synthesis of peptide analogues
    发明人:SHARPE ROBERT; SZELKE MICHAEL
    权利人:SHARPE ROBERT; SZELKE MICHAEL
    摘要:Compounds being analogues of a dipeptide in which the nitrogen atom of the linking amide group of the dipeptide is replaced by trivalent group ##STR1## and in which, optionally, the carbonyl function of this linking group is replaced by the divalent group --CH 2 -- are of value in the synthesis of isosterically modified peptides.

    专利号:US-9115179-B2
    优先权日:2012-06-22
    标题 :Synthesis of beta-turn peptidomimetic cyclic compounds
    发明人:LAMA TERESA; PASCAL JEANICK
    权利人:MIMETOGEN PHARMACEUTICALS INC
    摘要:The present invention relates to methods of preparing β-turn cyclic peptidomimetic compounds and intermediates thereof. Particularly, the present invention relates to a process for the synthesis of β-turn cyclic peptidomimetic compounds of formula I: n nwhere R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , L 2 , X, Y and n are as defined in the specification.n n The present invention provides a more efficient route for preparing β-turn cyclic peptidomimetic compounds and intermediates thereof.

    专利号:US-5362899-A
    优先权日:1993-09-09
    标题:Chiral synthesis of alpha-aminophosponic acids
    发明人:CAMPBELL DAVID A
    权利人:AFFYMAX TECH NV
    摘要:A stereospecific method of preparing alpha-aminophosphonic acids and derivatives thereof is provided. A protected amino acid is converted to a acyl aroyl or diacyl peroxide which spontaneously rearranges to form an alpha-amino ester. This rearrangement occurs stereospecifically with retention of configuration. The ester is subsequently converted to an appropriate leaving group and displaced with a phosphite yielding a chiral alpha-aminophosphonic acid or derivative. n Alpha-aminophosphonic acids are useful for the synthesis of peptide analogs that possess a phosphonate linkage in the place of an amide linkage. This substitution can impart protease resistance in therapeutic peptides thereby increasing the serum half-life.

    专利号:US-5446158-A
    优先权日:1989-01-11
    标题:Process for synthesis of FK-506 and tricarbonyl intermediates
    发明人:JONES TODD K; MILLS SANDER G; ASKIN DAVID; REAMER ROBERT A; DESMOND RICHARD; TSCHAEN DAVID M; VOLANTE RALPH P; SHINKAI ICHIRO
    权利人:MERCK & CO INC
    摘要:A process is described for the total synthesis of the macrolide immunosuppressant, FK-506, and important tricarbonyl process intermediates thereof. The tricarbonyl intermediates can be produced by the mild oxidation of 2,3-dihydroxy carboxylate compounds containing olefin moieties.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: ZINN WJ, SCHLEISSNER LA. THE EFFECTS OF DEXTROTHYROXINE IN DIABETES. Calif Med. 1964 Oct;101(4):240-5.
    2: Gage D, Bernard RD. Dextrothyroxine. N Y State J Med. 1972 Jun 15;72(12):1559.
    13:75-8. doi: 10.1177/000331976201300204. 49(1):1-7. doi: 10.1210/jcem-49-1-1. 1(7692):205-6. doi: 10.1016/s0140-6736(71)90948-2. 20(10):565-79. doi: 10.1177/000331976902001001.

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知